Ibrutinib-associated bleeding: pathogenesis, management and risk reduction strategies

J. J. Shatzel, S. R. Olson, D. L. Tao, Owen McCarty, Alexey Danilov, Thomas Deloughery

Research output: Contribution to journalReview article

44 Citations (Scopus)

Abstract

Ibrutinib is an irreversible inhibitor of Bruton's tyrosine kinase (Btk) that has proven to be an effective therapeutic agent for multiple B-cell-mediated lymphoproliferative disorders. Ibrutinib, however, carries an increased bleeding risk compared with standard chemotherapy. Bleeding events range from minor mucocutaneous bleeding to life-threatening hemorrhage, due in large part to the effects of ibrutinib on several distinct platelet signaling pathways. There is currently a minimal amount of data to guide clinicians regarding the use of ibrutinib in patients at high risk of bleeding or on anticoagulant or antiplatelet therapy. In addition, the potential cardiovascular protective effects of ibrutinib monotherapy in patients at risk of vascular disease are unknown. Patients should be cautioned against using non-steroidal anti-inflammatory drugs, fish oils, vitamin E and aspirin-containing products, and consider replacing ibrutinib with a different agent if dual antiplatelet therapy is indicated. Patients should not take vitamin K antagonists concurrently with ibrutinib; direct oral anticoagulants should be used if extended anticoagulation is strongly indicated. In this review, we describe the pathophysiology of ibrutinib-mediated bleeding and suggest risk reduction strategies for common clinical scenarios associated with ibrutinib.

Original languageEnglish (US)
Pages (from-to)835-847
Number of pages13
JournalJournal of Thrombosis and Haemostasis
Volume15
Issue number5
DOIs
StatePublished - May 1 2017

Fingerprint

Risk Reduction Behavior
Hemorrhage
Anticoagulants
PCI 32765
Lymphoproliferative Disorders
Vitamin K
Fish Oils
Platelet Aggregation Inhibitors
Vitamin E
Vascular Diseases
Aspirin
B-Lymphocytes
Anti-Inflammatory Agents
Therapeutics
Blood Platelets
Drug Therapy
Pharmaceutical Preparations

Keywords

  • agammaglobulinemia
  • blood platelets
  • hemorrhage
  • ibrutinib
  • lymphoma

ASJC Scopus subject areas

  • Hematology

Cite this

Ibrutinib-associated bleeding : pathogenesis, management and risk reduction strategies. / Shatzel, J. J.; Olson, S. R.; Tao, D. L.; McCarty, Owen; Danilov, Alexey; Deloughery, Thomas.

In: Journal of Thrombosis and Haemostasis, Vol. 15, No. 5, 01.05.2017, p. 835-847.

Research output: Contribution to journalReview article

@article{e113f145ce2a4a85abd5b29866edacdb,
title = "Ibrutinib-associated bleeding: pathogenesis, management and risk reduction strategies",
abstract = "Ibrutinib is an irreversible inhibitor of Bruton's tyrosine kinase (Btk) that has proven to be an effective therapeutic agent for multiple B-cell-mediated lymphoproliferative disorders. Ibrutinib, however, carries an increased bleeding risk compared with standard chemotherapy. Bleeding events range from minor mucocutaneous bleeding to life-threatening hemorrhage, due in large part to the effects of ibrutinib on several distinct platelet signaling pathways. There is currently a minimal amount of data to guide clinicians regarding the use of ibrutinib in patients at high risk of bleeding or on anticoagulant or antiplatelet therapy. In addition, the potential cardiovascular protective effects of ibrutinib monotherapy in patients at risk of vascular disease are unknown. Patients should be cautioned against using non-steroidal anti-inflammatory drugs, fish oils, vitamin E and aspirin-containing products, and consider replacing ibrutinib with a different agent if dual antiplatelet therapy is indicated. Patients should not take vitamin K antagonists concurrently with ibrutinib; direct oral anticoagulants should be used if extended anticoagulation is strongly indicated. In this review, we describe the pathophysiology of ibrutinib-mediated bleeding and suggest risk reduction strategies for common clinical scenarios associated with ibrutinib.",
keywords = "agammaglobulinemia, blood platelets, hemorrhage, ibrutinib, lymphoma",
author = "Shatzel, {J. J.} and Olson, {S. R.} and Tao, {D. L.} and Owen McCarty and Alexey Danilov and Thomas Deloughery",
year = "2017",
month = "5",
day = "1",
doi = "10.1111/jth.13651",
language = "English (US)",
volume = "15",
pages = "835--847",
journal = "Journal of Thrombosis and Haemostasis",
issn = "1538-7933",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Ibrutinib-associated bleeding

T2 - pathogenesis, management and risk reduction strategies

AU - Shatzel, J. J.

AU - Olson, S. R.

AU - Tao, D. L.

AU - McCarty, Owen

AU - Danilov, Alexey

AU - Deloughery, Thomas

PY - 2017/5/1

Y1 - 2017/5/1

N2 - Ibrutinib is an irreversible inhibitor of Bruton's tyrosine kinase (Btk) that has proven to be an effective therapeutic agent for multiple B-cell-mediated lymphoproliferative disorders. Ibrutinib, however, carries an increased bleeding risk compared with standard chemotherapy. Bleeding events range from minor mucocutaneous bleeding to life-threatening hemorrhage, due in large part to the effects of ibrutinib on several distinct platelet signaling pathways. There is currently a minimal amount of data to guide clinicians regarding the use of ibrutinib in patients at high risk of bleeding or on anticoagulant or antiplatelet therapy. In addition, the potential cardiovascular protective effects of ibrutinib monotherapy in patients at risk of vascular disease are unknown. Patients should be cautioned against using non-steroidal anti-inflammatory drugs, fish oils, vitamin E and aspirin-containing products, and consider replacing ibrutinib with a different agent if dual antiplatelet therapy is indicated. Patients should not take vitamin K antagonists concurrently with ibrutinib; direct oral anticoagulants should be used if extended anticoagulation is strongly indicated. In this review, we describe the pathophysiology of ibrutinib-mediated bleeding and suggest risk reduction strategies for common clinical scenarios associated with ibrutinib.

AB - Ibrutinib is an irreversible inhibitor of Bruton's tyrosine kinase (Btk) that has proven to be an effective therapeutic agent for multiple B-cell-mediated lymphoproliferative disorders. Ibrutinib, however, carries an increased bleeding risk compared with standard chemotherapy. Bleeding events range from minor mucocutaneous bleeding to life-threatening hemorrhage, due in large part to the effects of ibrutinib on several distinct platelet signaling pathways. There is currently a minimal amount of data to guide clinicians regarding the use of ibrutinib in patients at high risk of bleeding or on anticoagulant or antiplatelet therapy. In addition, the potential cardiovascular protective effects of ibrutinib monotherapy in patients at risk of vascular disease are unknown. Patients should be cautioned against using non-steroidal anti-inflammatory drugs, fish oils, vitamin E and aspirin-containing products, and consider replacing ibrutinib with a different agent if dual antiplatelet therapy is indicated. Patients should not take vitamin K antagonists concurrently with ibrutinib; direct oral anticoagulants should be used if extended anticoagulation is strongly indicated. In this review, we describe the pathophysiology of ibrutinib-mediated bleeding and suggest risk reduction strategies for common clinical scenarios associated with ibrutinib.

KW - agammaglobulinemia

KW - blood platelets

KW - hemorrhage

KW - ibrutinib

KW - lymphoma

UR - http://www.scopus.com/inward/record.url?scp=85017201249&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85017201249&partnerID=8YFLogxK

U2 - 10.1111/jth.13651

DO - 10.1111/jth.13651

M3 - Review article

C2 - 28182323

AN - SCOPUS:85017201249

VL - 15

SP - 835

EP - 847

JO - Journal of Thrombosis and Haemostasis

JF - Journal of Thrombosis and Haemostasis

SN - 1538-7933

IS - 5

ER -